Abstract:Introduction. In recent years, immune checkpoint inhibitors (ICIs) have attracted widespread attention and made breakthroughs in progress towards the treatment of various cancers. However, ICI therapy is selective, and its effects on many patients are not ideal. It is therefore critical to identify prognostic biomarkers of response to ICI therapy. The PI3K/Akt pathway plays important roles in tumor formation and metastasis. However, there are no published reports clarifying the relationship between PI3K/Akt pathway mutations and prognosis for colon adenocarcinoma (COAD) patients receiving immunotherapy. Methods. We collected data from a COAD cohort from The Cancer Genome Atlas (TCGA) database, including whole-exome sequencing (WES) data, RNA-seq data, and clinical data. We also collected data, including clinical prognosis and targeted sequencing data, from a cohort of COAD patients receiving immunotherapy. We collected 50 COAD patients (Local-COAD) from the Zhujiang Hospital of Southern Medical University and performed targeted sequencing. We analyzed the effects of PI3K/Akt pathway mutations on the patients' clinical prognosis, immunogenicity, and immune microenvironments. Gene set enrichment analysis (GSEA) was used to analyze the significantly upregulated and downregulated signaling pathways. We used these results to hypothesize potential mechanisms by which PI3K/Akt mutations could affect the prognosis of COAD patients. Results. Univariate and multivariate Cox analyses and Kaplan-Meier (KM) survival curves showed that patients with PI3K-Akt mutations had better overall survival (OS) than those without PI3K-Akt mutations. Genes with significant mutation rates in the two cohorts were screened by panoramic view. CIBERSORT was used to analyze changes in 22 types of immune cells to identify immune activated cells. Similarly, patients in the PI3K/Akt-mutated type (PI3K/Akt-MT) group had significantly increased immunogenicity, including increases in tumor mutation burden (TMB), neoantigen load (NAL), and MANTIS score. Using GSEA, we identified upregulated pathways related to immune response. Conclusion. PI3K/Akt pathway mutation status can be used as an independent predictor of response to ICI treatment in COAD patients. PI3K/Akt mutations are correlated with improved OS, higher immunogenicity, greater immune response scores, and increases in activated immune cells.

[Cell Balance Between Apoptosis and Proliferation in Colon Cancer and Its Correlation with Prognosis].

Measures of Cell Turnover (apoptosis and Proliferation) and Their Association with Survival in Gastric Cancer

Expression of Survivin and Its Correlation with Expression of Bcl-2 and P53 in Colorectal Adenocarcinoma

[Expression and Significance of Bmi-1 and Ki67 in Colorectal Carcinoma Tissues].

[Preliminary Study on Relationship among Apoptosis and Related Gene, Prognosis of Lung Cancer].

Influence of P57kip2 and Ki67 Expression on Invasive Properties of Colon Adenocarcinoma

Association Between Ki67 Expression and Therapeutic Outcome in Colon Cancer.

Apoptosis and proliferation in paired primary colorectal adenocarcinomas and their liver metastases

Expression Of Ki-67 And Pakt In Colorectal Cancer Tissues And Their Clinical Significance

Combined proliferation and apoptosis index provides better risk stratification in breast cancer

The relationship between ABI1 upregulation and clinicopathological features and prognosis of colorectal adenocarcinoma

An Apoptosis-Related Gene Prognostic Index for Colon Cancer

Prognostic Significance of DNA Ploidy in Patients with Stage II Colorectal Cancer

Prognostic role of p27 Kip1 and apoptosis in human breast cancer

Expression of P27 Gene and Proliferation of Colorectal Carcinoma

Expression of P27kipl and Ki67 in colonic cancer and their clinical significance

Prognostic significance of bcl-2 and p53 expression in colorectal carcinoma

Apoptosis and KI 67 index correlate with preoperative chemotherapy efficacy and better predict the survival of gastric cancer patients with combined therapy

Cell Proliferation, Apoptosis and the Related Regulators P27, P53 Expression in Hepatocellular Carcinoma

Expression of Bcl-Xl and Cyclin D1 in Pancreatic Carcinoma and Their Relationship with Signal Transducer and Activator of Transcription-3(Stat3)

Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment